Only a few critical oncogenes have been identified in the more commonly occurring cases of sporadic breast cancer. We provide evidence that EN2 is ectopically expressed in a subset of human breast cancer and may have a causal role in mammary tumorigenesis. Nontumorigenic mammary cell lines engineered to ectopically express En-2 have a marked reduction in their cycling time, lose cell contact inhibition, become sensitive to 17-AAG treatment, fail to differentiate when exposed to lactogenic hormones and induce mammary tumors when transplanted into cleared mammary glands of syngeneic hosts. RNA interference studies suggest that EN2 expression is required for the maintenance of the transformed phenotype of a human breast tumor cell line.
Introduction
Breast cancer is one of the most frequent human malignancies in the Western world. The pathogenesis of this disease is thought to involve multiple genetic and epigenetic events. In spite of recent advances in the assessment of breast cancer risk, through the identification of crucial susceptibility genes (BRCA1/2, PTEN, P53), these account for less than 5% of all breast cancer cases and may not be associated with the more commonly occurring sporadic breast cancers (Baselga and Norton, 2002) . The discovery of bona fide primary genetic lesions underlying sporadic breast cancer development remains a major challenge. This is due, at least in part, to the marked cytogenetic complexity seen in advanced breast cancer, precluding investigators from readily identifying primary causative genetic events in breast cell transformation (Tognon et al., 2002) .
A number of oncogenes and tumor suppressors have been associated with breast cancer. The c-MYC gene is amplified and/or overexpressed in a high proportion of human breast cancer, although the frequency of these alterations varies greatly (Liao and Dickson, 2000) . ErbB2 is also amplified and subsequently overexpressed in 20-30% of human breast cancers, and overexpression of ErbB2 is correlated with a poor clinical prognosis of both node-positive and node-negative tumors (Hutchinson and Muller, 2000) . The Cyclin D1 gene is amplified in 15-20% of human breast cancers (Bieche et al., 1999) . As the oncogenes located at amplified chromosomal regions are rarely amplified in benign breast disease (Lizard-Nacol et al., 1995) , they may represent later events in the multistep progression associated with the development of breast cancer.
In rodents, it has been possible to identify several breast cancer-initiating oncogenes by the characterization of proviral integration sites of the mouse mammary tumor virus (MMTV). One such locus is Wnt-1, which, when overexpressed, leads to mammary hyperplasia and subsequent generation of adenocarcinomas (Nusse and Varmus, 1982) . Although expression of WNT-1 itself has not been reported in normal or neoplastic human breast tissue, other WNT genes have been detected in subsets of human breast cancers (Huguet et al., 1994) . Wnt-1 encodes a secreted growth factor that initiates a signaling cascade that results in transcriptional activation mediated by b-catenin/Tcf complexes (Cadigan and Nusse, 1997) . b-Catenin/Tcf-mediated transcription has also been implicated in human cancer, with some targets relevant to breast carcinogenesis identified such as c-MYC and cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999) . The observation that Wnt-1 is a mouse mammary oncogene and that the downstream mediator b-catenin is often stabilized in certain human malignancies fuels the ongoing search for additional targets of this pathway, such as the Engrailed genes, that might also be implicated in breast cancer.
The mouse Engrailed-1 (En-1) and Engrailed-2 (En-2) genes encode homeobox-containing transcription factors that are the murine homologs of the Drosophila segment polarity gene engrailed. En-1 is first expressed in the presumptive mid/hindbrain around 8.0 dpc and continues to be expressed, together with En-2, in overlapping patterns during midbrain development (McMahon et al., 1992) . En-2 expression is restricted to the central nervous system and branchiolar arches during embryogenesis and En-2 null mutants are viable but harbor reductions in cerebellar size (Davis and Joyner, 1988; Joyner et al., 1991) .
En and other homeobox-containing genes clearly occupy a prominent position in the developmental regulatory hierarchy, yet they have received little attention with respect to mammary gland organogenesis and cancer. In the present study, we show that EN2 (but not EN1) is ectopically expressed in a subset of human breast cancer and in a large proportion of breast cancer cell lines and that its ectopic expression readily transforms mammary epithelial cells in vitro and promotes adenocarcinoma formation in vivo. We also provide evidence of its critical function in a breast cancer cell line.
Results
Engrailed genes are rarely activated in Wnt-1-induced mammary tumors
As En-1 and En-2 are functional targets of Wnt-1 in mouse embryogenesis and several different groups of homeodomain proteins have been implicated as causative oncogenes in cancer (Lewis, 2000) , we initially sought to determine whether En-1 or En-2 was implicated in Wnt-1-induced mouse mammary hyperplasia observed in MMTV-Wnt-1 transgenics (Tsukamoto et al., 1988) . Neither En-1 nor En-2 was detected by Western blot or RT-PCR analyses in hyperplastic mammary glands derived from nulliparous hemizygous MMTV-Wnt-1 transgenic females (n ¼ 4; Figure 1a , lanes 2, 3, 5 and 7). In addition, only one of three tumors arising from the MMTVWnt-1 transgenics expressed En-1 (not shown), while no expression of En-2 was detected in these primary tumors ( Figure 1a) . Thus, while En-1 and En-2 are downstream and responsive to Wnt-1 signaling in embryogenesis, it seems unlikely that they contributed to tumor formation.
Although En-1 shows a specific temporal expression pattern in the normal adult mouse mammary gland (NM and GS, manuscript in preparation), En-2 expression was not detectable in the normal mouse gland (Figure 1b) . With a detection sensitivity nearing 0.01% of the cells (Figure 2a ), EN2 was also not detected in normal human mammary tissues derived from reduction mammoplasty (n ¼ 11; Figure 2b and c). As detailed below however, the presence of EN2 protein in the human breast cancer cell line MCF7 (Figure 3a ) led us to investigate its expression in primary human breast tumors.
EN2 is ectopically expressed in human breast cancer samples
Using semiquantitative RT-PCR analysis, we found that EN2 expression was not limited to MCF7 cells since a large proportion (7/12 or 58%) of established breast carcinoma cell lines expressed this gene (Figure 3b ). Of the EN2-positive cell lines, four were derived from adenocarcinomas (MDA-MB-435S, BT-20, MDA-MB-436 and MCF7), one from ductal carcinoma (BT-474), and two were designated as fibrocystic breast tissue (MCF 10A and MCF-12A). The latter two lines, although originally derived from hyperplastic breast tissue and not carcinomas, have evolved from the initial immortalized normal cell line as they now form colonies in soft agar, a characteristic frequently associated with transformed cells (data not shown). Western blot analyses confirmed the presence of EN2 and the absence of EN1 in all of these cell lines (data not shown).
To determine whether EN2 was also expressed in primary human breast tumors, semiquantitative RT-PCR analysis was performed on RNA derived from frozen breast biopsies. Two of the 23 primary RT-PCR analysis was used to investigate En-2 expression at several different developmental stages in the mouse mammary gland. HC11 mammary epithelial cells engineered to express En-1 or En-2, E12.5 dpc embryonic bodies without heads (Ed12.5 Body), where En-1 is exclusively expressed, and adult mouse cerebellum, where En-2 is exclusively expressed, were included as specificity controls Engrailed-2 in breast transformation NL Martin et al tumors initially analysed expressed EN2 at levels comparable to that observed in MCF7 cells (Figure 3c) . Importantly, the normal tissue adjacent to these two tumors did not express EN2 (Normal 3 and 4; Figure 3c , lane 1 and 16, respectively). These observations were confirmed by immunohistochemistry, which revealed strong EN2 nuclear staining in the neoplastic epithelial cells within the tumors only and not in the normal adjacent tissue (Figure 3d, compare T3 and T4 to N3 and N4, respectively) . Histologically, these two tumors were defined as adenocarcinoma (T3) and infiltrating ductal carcinoma, inflammatory type (T4). Our analysis of human breast tumors and normal adjacent samples was expanded to better define an estimated frequency of EN2 expression in breast cancer. While EN2 was not detected in any of the normal samples analysed (n ¼ 19 total), 4/59 of the additional tumors expressed EN2 (not shown). All four additional EN2-positive tumors were infiltrating ductal carcinomas. Thus, EN2 is ectopically expressed in a subset of human breast cancer representing approximately 7% in the population tested.
Ectopic expression of En-2 readily transforms mammary epithelial cell lines
To investigate the possible oncogenic role of En-2 in normal breast epithelial cells, we first engineered, by retroviral gene transfer, its ectopic expression in two immortalized, nontransformed, anchorage-dependent mammary epithelial cell lines, HC11 and C57MG. HC11 cells were chosen as they have retained both the ability to differentiate in vitro upon stimulation with lactogenic hormones and to generate epithelial outgrowths when transplanted back into the cleared (gland-free) Engrailed-2 in breast transformation NL Martin et al fat pads of syngeneic hosts, as observed with primary mammary epithelial cells (Humphreys and Rosen, 1997) . Additionally, both HC11 and C57MG cells have been shown to acquire anchorage-independent growth when transduced with oncogenes involved in breast cancer (c-erbB-2 in HC11 (Hynes and Stern, 1994) and Wnt-1 in C57MG (Brown et al., 1986) ). The resulting levels of En-2 expression in HC11 selected polyclonal populations transduced with En-2-containing retrovirus were comparable to levels of EN2 seen in MCF7 and endogenous levels seen in the cerebellum (see Supplementary Figure 1 online). HC11 and C57MG cells ectopically expressing En-2 proliferated significantly faster when compared to parental untransduced cells or Neo-transduced cells (Figure 4a and b) . Furthermore, ectopic En-2 expression conferred anchorage-independent growth to both cell lines (Figure 4c ). En-2-dependent loss of cell contact inhibition was also observed in HC11 cells (Figure 4d ). All of the above effects produced by En-2 expression were reproduced, albeit to a lesser extent, with the paralogous gene En-1 (Figure 4 ). Similar to Hox proteins, Engrailed proteins can bind target DNA as a heterodimer with Pbx1b, another homeodomain-containing protein Murre, 1996, 1997) . Studies in our lab have shown that Hox-induced proliferation of fibroblasts is dependent on its interaction with Pbx . Consistent Figure 4f ). Ectopic expression of En-2 thus inhibits the DIP-induced differentiation program of HC11 cells in vitro.
We also examined the effect of 17-AAG, an inhibitor of Hsp90 that selectively kills cancerous cells, on the growth of these mammary epithelial cell lines (Neckers and Lee, 2003) . Proliferation of both nontransformed HC11 and C57MG cell lines was not significantly affected by 17-AAG treatment, yet the proliferation advantage conferred by En-2 expression in these two cell lines is abrogated by 17-AAG exposure (Figure 5a and  b) . Interestingly, in the case of En-2-expressing C57MG cells, exposure to 17-AAG not only reverted the proliferative advantage conferred by En-2, but also inhibited proliferation of these cells to levels that are now below those measured in the untransduced parental cells (Figure 5b ). Since Hsp90 found in tumor cells has a much higher affinity for 17-AAG than the Hsp90 found in normal cells, this supports the observation that EN-2 behaves as an oncogene in vitro and readily transforms these mammary epithelial cells.
Transplanted En-2-transduced HC11 cells generate adenocarcinomas that metastasize HC11 mammary cells introduced into surgically cleared fat pads of female hosts, under endogenous hormonal influences and within the natural microenvironment, will generate mammary epithelial outgrowths (Humphreys and Rosen, 1997). Using this technique in an initial cohort, we observed that the majority (14/16) of mammary glands reconstituted with either En-2-or En-2 þ PBX1b-transduced HC11 cells developed palpable adenocarcinomas at 14 weeks, while those receiving control HC11 cells (either Neo-transduced or parental cells) produced reconstituted glands but remained tumor-free ( Figure 6A ).
To test for tumor progression in this in vivo tumor model, a second cohort of mice were generated and killed at 21 weeks post transplantation. Once again, the control groups remained tumor-free. The En-2 and En-2 þ PBX1b groups developed large adenocarcinomas (32/34) with extensive fibrosis and neo-vascularization ( Figure 6A and B). Macroscopic metastases were observed in multiple sites, with regional nodes and lungs being preferentially targeted by the cells initiating metastatic growth (n ¼ 6/32 mice or 19%). Metastases were also detected in the spleen and the mesenteric lymph nodes in certain cases (hollow diamonds around black diamonds indicate mice with metastases in Figure 6B ).
The clonal composition of the tumors and of adjacent portions of the reconstituted glands was investigated using Southern blot analysis. Proviral integration analysis showed that during the progression to tumorigenesis, typically 1-2 distinctive clones contributed to the population of the cells comprising the tumor. Such clones are distinguished by different autoradiographic signals visible at distinct sizes in different tumors (e.g., see two different signals in lane 7 in Figure 6C) . From the five different tumors shown here, at least five distinct clones were identified (see clones 'a' to 'e' in Figure 6C ) indicating that there were no prominent clones in the initiating population. Interestingly, clone 'a', confirmed to be the same clone with a second digest (not shown), was found in two different hosts (2.1 and 2.3 in Figure 6C ). The presence of this clone in two different Figure 5 The proliferative advantage that accompanies ectopic En-2 expression in mammary epithelial cells is lost after exposure to 17-AAG. (a, b) Selective in vitro antiproliferative activity of 17-AAG in En-2-transduced HC11 and C57MG mouse mammary cell lines. Proliferation curves were generated from total cell counts taken 3 and 6 days following the addition of either DMSO or 5 mm 17-AAG Engrailed-2 in breast transformation NL Martin et al recipients could reflect a selective event that occurred in vitro prior to transplantation. Our inability to detect this clone in the polyclonal population from which it is derived ( Figure 6C , lane 1) suggests that a different selective process occurs in vivo versus in vitro and that additional genetic events were required for the development of overt mammary carcinomas in this model.
Interestingly, clones that contributed to tumor formation were different from the clones that contributed to nonhyperplastic mammary outgrowths in the more -transduced HC11 cells also tended to display clonal reconstitution (data not shown). Together, these results suggest that reconstitution of typical epithelial breast structures by HC11 cells depends on the selection of a subset of 'stem' cells in this population (heterogeneity) or, alternatively, that these cells require adaptation to grow in vivo.
The clonal composition of metastases was generally identical to that of the dominant clone present in the tumor (data not shown). Importantly, metastases mostly occurred in mice that harbored large (>4 cm 3 ) tumors (see Figure 6B ). This suggests that further genetic events were needed for the tumor cells to acquire the ability to metastasize and validates En-2 as a candidate oncogene that fosters conditions required for tumor progression in vivo.
Small interfering RNA-mediated suppression of EN2 inhibits proliferation of human breast cancer cells
We next sought to determine the effect of knocking down EN2 expression in one of the human breast cancer-derived cell lines using an RNA interference (RNAi) approach. The small interfering RNAs (siRNAs) appear to mimic intermediates in the RNAi pathway and can silence genes in somatic cells without activating nonspecific suppression by double-stranded RNA-dependent protein kinase (Elbashir et al., 2001) . MDA-MB-435S cells, which express high levels of EN2 (Figure 3b ), were chosen as it was possible to achieve more than 90% transfection efficiency in these cells. Transient transfection of the synthetic siRNA directed against EN2 resulted in a reproducible and complete ablation of the protein within 48 h, which lasted for up to 12 days (Figure 7a and data not shown). Microarray analysis comparing parental MDA-MB-435S cells and siEN2-transfected-MDA-MB-435S cells showed that siRNA exposure did not activate interferon genes such as MHC class I, oligoadenylate synthetase or enolase and that off target effects are unlikely since there was very little difference in the global transcriptome in response to siRNA treatment (data not shown).
siEN2-transfected-MDA-MB-435S cells uniquely exhibited a more flattened and retractile morphology while cells transfected with a control scrambled siRNA displayed little observable change in their transformed morphology (Figure 7b) . Importantly, the suppression of EN2 in these cells also resulted in a reproducible and significant decrease in their proliferation rate when compared to controls (those transfected with the scramble siRNA or mock-transfected cells; Figure 7c ). In line with these results, cell cycle analysis revealed a two-fold reduction in the proportion of siEN2-transfected cells in S phase when compared to controls (30 versus 16% respectively, Po0.01; Figure 7d ). This reduction in proliferation is not accompanied by an increase in apoptosis, as revealed by Annexin V staining and the lack of an increasing sub-G 1 population (Figure 7d, right panel) . Persistent expression of EN2 is thus required even in this well-established breast cancer cell line.
Discussion
We have shown that EN2 is expressed in the majority of human breast tumor-derived cell lines and that it is ectopically expressed in B7.3% of primary breast cancers. We have also shown that ectopic expression of En-2, at levels similar to those observed in primary tumors, readily transforms HC11 and C57MG cells and inhibits a differentiation program in HC11 cells that is normally induced by lactogenic hormones. En-2 thus enhances proliferation and inhibits differentiation of mammary epithelial cells. Furthermore, our in vivo studies and clonal analysis of mammary adenocarcinomas occurring with En-2-transduced HC11 cells generated a unique model of breast cancer progression from selection of long-term repopulating cells to tumor development and to metastasis. RNAi-mediated downregulation of EN2 in a human breast tumor-derived cell line leads to a dramatic reduction in cell proliferation and loss of transformed morphological characteristics.
To our knowledge, EN2 is the first candidate oncogene identified in breast cancer, which is not normally expressed in breast epithelium. Southern blot analysis of genomic DNA isolated from the seven different EN2-positive human breast cancer cell lines studied herein failed to reveal any anomaly, suggesting that neither rearrangement nor amplification is responsible for ectopic EN2 expression. Although the basis for overexpression of MYC, Cyclin D1 and ErbB2 is often amplification of the gene, overexpression is also observed in the absence of amplification (Ross et al., 2003) . Epigenetic modification of the EN2 locus remains a real possibility. Very little is known about upstream regulators of En, in addition to Wnt, and our studies suggest that the activation of one Wnt member, Wnt-1, is not involved since En-2 expression is not found in mouse mammary tumors induced by Wnt-1 and this oncogene is not expressed in human breast carcinomas. It will therefore be challenging to identify the exact mechanism(s) underlying the ectopic expression of EN2, but standard epigenetic tests will likely reveal that the locus is rendered transcriptionally active. It will be interesting to discriminate whether EN2 is activated in preneoplastic breast lesions as both MCF 10A and MCF-12A express EN2 and are derived from women with epithelial hyperplasia of the breast. This is in contrast with other oncogenes (e.g., ErbB2) that are rarely detected within early lesions or benign breast disease (Ingvarsson, 1999) and may indicate that ectopic EN2 expression occurs early in breast cancer.
The reasons for the high incidence of EN2 expression in breast cancer cell lines (as opposed to primary tumors) are not clear. Perhaps a selection process (proliferation, independence of stroma, etc.) favors the emergence of cancer cell lines that express this gene. As the notion of breast cancer stem cells is emerging (Al Hajj et al., 2003) , it will become interesting to investigate whether EN2 determines the proliferative activity of these tumor stem cells, as we recently showed for Bmi-1 in leukemic stem cells (Lessard and Sauvageau, 2003) .
Of interest, EN2 was also detected in SAGE libraries derived from human brain glioblastoma, colon and ovarian carcinoma (Library numbers NCI CGAP Bm23, NCI CGAP Co16 and CL ES2-1, respectively, http://www.ncbi.nlm.nih.gov/UniGene). It will be essential to analyse whether EN2 is also ectopically expressed in other epithelial tumors as the observations described herein may be generalized to other carcinomas. Importantly, it will be critical to determine an even more accurate frequency of EN2 ectopic expression in breast cancers using a larger number of specimens and to assess whether its expression correlates predominantly to infiltrating ductal carcinomas. Similar to the current rationale that herceptin and 17-AAG, in combination, will increase the taxol response even further in HER-2-overexpressing breast and prostate cancers, the combination of 17-AAG and siRNA against EN2 may constitute a strong assault against EN2-positive breast Although siRNA directed against EN2 offers great specificity in cancerous lesions detected early, as we have shown that EN2 is ectopically expressed in breast cancer, the addition of 17-AAG may also affect those tumors that have evolved to evade the toxic effects of single molecularly targeted agents. This approach could have great clinical benefit as if it does not kill the cancer cells, it might leave them sufficiently debilitated and more sensitive to chemotherapy and radiotherapy (Neckers and Lee, 2003) .
Materials and methods

Transgenic mice
The generation of MMTV-Wnt-1 transgenic mice has been reported previously (Tsukamoto et al., 1988) and the mice were purchased from The Jackson Laboratory (FVB/N hybrid background, stock #002934). MMTV-Wnt-1 mice were genotyped by Southern blot analysis of BamHI-digested tail DNA using a 904-bp Kpnl-Sphl fragment of SV40 poly(A) DNA. BALB/c mice were acquired from Harlan Labs (Indianapolis, IN, USA). All animals were maintained and bred in ventilated microisolator cages, provided with sterilized food and acidified water in the specific pathogen-free (SPF) animal facility of the Clinical Research Institute of Montreal (IRCM).
Cell lines
The HC11 mammary epithelial cell line is a clonal derivative of the COMMA-1D cell line, derived from mammary tissue of a mid-pregnant BALB/c female (Danielson et al., 1984; Ball et al., 1988) . The C57MG cell line was derived from glands of a 23-week-old retired C57BL/6 breeder (Vaidya et al., 1978) . MCF7, MDA-MB-231, SK-BR-3, MDA-MB-468, MDA-MB-435S, MDA-MB-436 and BT-20 human epithelial cell lines were derived from breast adenocarcinomas. T-47D and BT-474 human epithelial cell lines were isolated from ductal carcinomas. MCF 10A and MCF-12A human epithelial cell lines were derived from fibrocystic breast tissue and both lines have been reported to form colonies in soft agar. The HBL 100 human epithelial cell line was originally derived from breast milk, yet also forms colonies in soft agar. C57MG, HC11, T-47D, HBL 100 and MCF7 lines were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 10 ng/ml of epidermal growth factor and 10 mg/ml of insulin. MDA-MB-435S, MDA-MB-436 and MDA-MB-468 lines were grown in Lebowitz-L15 medium supplemented with 10% FCS. MCF 10A and MCF-12A lines were grown in F12 HAM : DMEM (1 : 1) medium supplemented with 5% FCS. The BT-20 line was grown in aMEM medium supplemented with 10% FCS.
Generation of recombinant retroviruses and infection of mammary cell lines
The entire coding regions of the mouse En-1 (nucleotides(nt) 274-1578; accession no. L12703, #552) and En-2 (nt 1-1315; accession no. L12705, #547; the mouse En-2 protein shares 90% amino-acid sequence identity with the human EN2 protein) cDNAs were introduced into the HpaI and HpaIBglII sites, respectively, downstream of the retroviral promoter contained within the 5 0 long terminal repeat (LTR) of the MSCVneoEB retroviral vector, which confers G418 resistance under the control of the phosphoglycerate kinase (PGK) promoter. The MSCV-human PBX1b-PGK-PAC retroviral vector (which confers puromycin resistance) was described previously . High-titer helper-free recombinant retroviruses were produced from BOSC-23 viral packaging cells and tested as previously reported . HC11 and C57MG cell lines were infected by exposure to filtered (0.2 mm, low-protein binding filter, Millipore, Bradford, MA, USA) viral supernatant in the presence of 6 mg/ml polybrene (Sigma). Transduced cells were selected and maintained in 220 and 260 mg/ml of G418 for HC11 and C57MG lines, respectively, or 2.5 mg/ml puromycin, or both drugs concurrently, as appropriate for selection of virus-encoded selectable markers.
Southern, Northern and Western blot analysis
To assess proviral integration, Southern hybridization analyses were performed as described previously (Pawliuk et al., 1994) . Genomic DNA (10 mg) was digested with Kpnl or Nhel, which cleaves in both flanking LTRs to release the provirus. Membranes were hybridized with Neo-or Puro-specific probes labeled with 32 P-dCTP by random primer extension as described (Lawrence et al., 1995) . Following autoradiography, blots were stripped and hybridized using a probe specific to HoxA9 (1.1 kb HindIII fragment) to assess loading. For Northern blot analysis, 10 mg total RNA isolated with TRIzol (GIBCO) was separated on a 1% formaldehyde-agarose gel as described (Kroon et al., 1998) and hybridized with a 186-bp BglII En-1 cDNA (#552) probe, a 254-bp BglII-SstI En-2 cDNA (#530) probe and a 1.6-kb BglII-Eco RI PBX1b cDNA (#448) probe. After autoradiography, the blots were stripped and rehybridized with an oligonucleotide complementary to 18S rRNA (Kroon et al., 1998) . For Western blot analysis, total and nuclear extracts were prepared as reported previously (Thorsteinsdottir et al., 1999) . In all, 100 mg of total protein and 40 mg of nuclear aliquots of protein were separated by SDS-PAGE as described (Thorsteinsdottir et al., 1999) . En proteins were detected with aEnhb-1 antisera (which detects both 41 kDa mouse En-1 and human EN1, and 55 kDa mouse En-2 and human EN2 proteins) as described . PBX1b proteins were detected with an anti-PBX1 polyclonal antibody (P-20; cat# sc-889; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). As a control for loading, all membranes were stripped and hybridized with aPTP1D (protein-tyrosine phosphatase 1D; P54420; BD PharMingen, Mississauga, Canada).
cDNA generation, amplification and analysis
Total RNA was isolated from adult mouse cerebellum, mouse mammary glands, cell lines, frozen human primary breast tumors, adjacent normal breast samples and frozen human reduction mammoplasty tissue using TRIzol. Reverse transcription and amplification of 0.1 mg of the resulting total RNA were performed as described previously (Sauvageau et al., 1994) . Single-copy probes corresponded to a 436-bp fragment of the mouse b-casein cDNA (nt 4871-5307; accession no. M26940 X13484, #1051) and Actin, isolated as described by Sauvageau et al. (1994) . The amplification of Actin was used as a control for both quality and quantity of templates in each sample. To demonstrate that the amplification was solely from cDNA and not from DNA contamination, a control that contained RNA but no reverse transcriptase (No RT) was included in each experiment. Specific RT-PCR for En-1 was carried out after the reverse transcription and tailing step by amplifying En-1 with primers (forward, 5 0 -CGG TTG CAA AAA GGA ACA-3 0 ; reverse, Engrailed-2 in breast transformation NL Martin et al 5 0 -AGC TTC CTG GTG CGT GGA, 551-bp product). The amount of reverse transcription mixture used in the En-1-specific PCR was equalized by the amplification of Actin cDNA (forward, 5 0 -CTC CAT CGT GGG CCG CTC TAG-3 0 ; reverse, 5 0 -GTA ACA ATG CCA TGT TCA ATG GGG-3 0 ; 137-bp product).
Immunohistochemistry
Frozen sections were cut at 5 mm and were subsequently fixed briefly in paraformaldehyde (PFA). Immunohistochemistry was performed using a three-step streptavadin-biotin peroxidase method and antigen retrieval was carried out by microwave heating in citrate buffer. Primary antibody rabbit anti-mouse polyclonal aEnhb-1 was used at a final dilution of 1/500. Biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories, Burlingame, CA, USA) was used at a final dilution of 1/150, and revealed using streptavidinhorseradish peroxidase (NEL 750, NEN) at 1/1000. Slides were counterstained with methyl green.
Soft agar colony formation, contact inhibition and proliferation assays
For proliferation assays, the selected HC11 and C57MG polyclonal transduced cell populations were trypsinized and replated at 3 Â 10 5 and 5000 cells per 10 cm 2 dish in RPMI 1640 with 5% FBS, for 3 and 6 days of growth respectively, and subsequently starved, serum stimulated and counted as described previously . For colony assays, the cells were grown for 3 days in the absence of antibiotic selection and then 2 Â 10 4 cells were plated in RPMI 1640 medium supplemented with 10% FCS, 10 ng/ml of epidermal growth factor and 10 mg/ml of insulin containing 0.3% Agar Noble into 35 mm 2 Petri dishes containing a layer of solidified 0.6% agar. Colonies were scored 21 days after being plated using a surface area that corresponded to 1/8 of the 35 mm 2 dish using an inverted microscope. For the contact inhibition assay, selected HC11 polyclonal transduced cell populations were trypsinized and replated at near confluence in 10 cm 2 dishes in RPMI 1640 with 10% FBS. Total cell counts were taken 7 days later when dense foci were readily visible in the cultures that no longer displayed contact inhibition and continued to grow.
Lactogenic hormone stimulation of HC11 mammary epithelial cells HC11 and HC11 cells expressing En-2 were grown to confluency in 10 cm 2 dishes and maintained for 3 days in normal media. Confluent cultures were washed and incubated for 18 h in serum-free media (RPMI 1640 containing 1 mg/ml fetuin and 10 mg/ml transferrin) followed by 3, 6 and 9 days of treatment with induction medium (RPMI 1640 containing 10 À6 M dexamethasone, 5 mg/ml insulin and 5 mg/ml ovine prolactin/luteotropic hormone; Sigma) as described (Cella et al., 1998) . Parallel unstimulated controls were subjected to the same regimen but were kept in RPMI 1640 with 5% FCS after serum-free starvation. The morphological changes in HC11 cells expressing En-1, En-1 þ PBX1b, En-2 and En-2 þ PBX1b were scored on cytospin preparations containing 150 000 cells (n ¼ 4 slides for each population).
Transplantation of HC11 transduced cells into syngeneic hosts
Selected polyclonal populations of HC11 cells transduced with En-2, En-2 þ PBX1b, PBX1b, Neo and untransduced HC11 cells were collected from 10 cm 2 dishes and resuspended in normal growth medium at a final concentration of 5 Â 10 5 cells/ 10 ml. Using a beveled syringe, the cells were injected into the cleared fat pads of female BALB/c syngeneic hosts, just above the lymph node, in a volume of 10 ml. The surgical procedures for clearing the endogenous mammary epithelium from the #4 (inguinal) fat pads of 3-week-old female mice have been described (DeOme et al., 1959) . In each case, whole-mount preparations of the excised host mammary epithelium were generated to verify complete removal. Two cohorts of mice were killed at 14 and 21 weeks post transplantation, respectively, and the glands were surgically removed. Wholemount preparations and subsequent sections were produced from the reconstituted glands in the first cohort. In the second cohort, the majority of the resulting tumors, different portions of the reconstituted glands and potential sites of metastases were either fixed in paraffin and subsequently sectioned, or used for DNA extraction.
Whole mounts and tumor histology
Inguinal mammary glands were resected and flatten fixed in Carnoy's fixative, defatted in ethanol and acetone, rehydrated and stained in Carmine red. The mammary whole mounts were reprocessed for paraffin embedment and 5 mm sections were prepared. Tumors and potential sites of metastases (brain, lung, femur, spleen, lymph nodes and the #5 mammary gland) were fixed overnight in 4% PFA, embedded in paraffin, sectioned at 5 mm and stained by H&E.
RNA interference studies
The 21-nt human EN2 target sequence used to design the synthetic siRNA was 5 0 -AAC TTC TTC ATC GAC AAC ATC-3 0 . The selected sequence was subjected to a BLAST search against the human genome sequence to ensure that only EN2 would be targeted. The 21-nt sequence constituting the control scrambled siRNA (siCTRL) was 5 0 -AA GCG CGC TTT GTA GGA TTC G-3 0 . Synthetic siRNA oligonucleotides were purchased from Dharmacon (Lafayette, CO, USA). MDA-MB-435S cells were regularly passaged to ensure exponential growth and were passaged the day before transfection. Subconfluent MDA-MB-435S cells were transfected with 150 nM siRNA/6 cm 2 dish and fresh media were provided 36 h after (details of the transfection procedure are available upon request to SM). Whole-cell extracts were prepared 3, 5, 7, 9 and 12 days after transfection, separated on a 10% SDS-PAGE and immunoblotted to reveal EN2 protein.
The same membrane was immunoblotted with antibody against b-tubulin as a control for loading. Cells were harvested for flow cytometry and plated for proliferation assays 3 days after transfection in at least three independent experiments.
Cell cycle analysis and Annexin V staining MDA-MB-435S cells were trypsinized 3 days post-transfection, washed twice with PBS and incubated for 30 min on ice in hypotonic DNA staining solution (0.1% sodium citrate, 0.3% NP-40, 0.02 mg/ml RNase A, 50 mg/ml propidium iodide). Stained nuclei (10 000/sample) were analysed by flow cytometry. Parallel 6 cm 2 dish were trypsinized, washed twice with PBS and incubated for 15 min on ice in Annexin V binding buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2, 1.8 mM CaCl 2 , 2.5 mg/ml Annexin V-FITC; 556419 BD PharMingen, 50 mg/ml propidium iodide). Stained cells (10 000/sample) were analysed by flow cytometry to detect phosphatidyl serine exposure and damaged cell membranes.
